Literature DB >> 25355454

A nationwide survey of PMM2-CDG in Italy: high frequency of a mild neurological variant associated with the L32R mutation.

Rita Barone1, M Carrozzi, R Parini, R Battini, D Martinelli, M Elia, M Spada, F Lilliu, G Ciana, A Burlina, V Leuzzi, M Leoni, L Sturiale, G Matthijs, J Jaeken, M Di Rocco, D Garozzo, A Fiumara.   

Abstract

PMM2-CDG (PMM2 gene mutations) is the most common congenital disorder of N-glycosylation. We conducted a nationwide survey to characterize the frequency, clinical features, glycosylation and genetic correlates in Italian patients with PMM2-CDG. Clinical information was obtained through a questionnaire filled in by the referral physicians including demographics, neurological and systemic features, neuroimaging data and genotype. Glycosylation analyses of serum transferrin were complemented by MALDI-Mass Spectrometry (MALDI-MS). Between 1996 and 2012, data on 37 Italian patients with PMM2-CDG were collected. All the patients with a severe phenotype were unable to walk unaided, 84 % had severe intellectual disability and 81 % microcephaly. Conversely, among 17 mildly affected patients 82 % had independent ambulation, 64 % had borderline to mild intellectual disability and 35 % microcephaly. Epilepsy and stroke-like events did not occur among patients with the mild phenotype. The rate and extent of systemic involvement were more pronounced in severely affected patients. The L32R misfolding mutation of the PMM2 gene occurred in 70 % of the patients with the mild phenotype and was associated with a less severe underglycosylation of serum Tf at MALDI-MS analyses. Despite their different disease severity, all patients had progressive (olivo)ponto-cerebellar atrophy that was the hallmark clinical feature for the diagnosis. A mild neurological phenotype of PMM2-CDG marked by preserved ambulatory ability and autonomy and associated with L32R mutation is particularly frequent in Italy. PMM2-CDG should be considered in patients with even mild developmental disability and/or unexplained progressive cerebellar atrophy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25355454     DOI: 10.1007/s00415-014-7549-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  37 in total

1.  Congenital disorder of glycosylation type Ia: a clinicopathological report of a newborn infant with cerebellar pathology.

Authors:  E Aronica; A A M W van Kempen; M van der Heide; B T Poll-The; H J van Slooten; D Troost; J M Rozemuller-Kwakkel
Journal:  Acta Neuropathol       Date:  2005-02-16       Impact factor: 17.088

2.  The molecular landscape of phosphomannose mutase deficiency in iberian peninsula: identification of 15 population-specific mutations.

Authors:  B Pérez; P Briones; D Quelhas; R Artuch; A I Vega; E Quintana; L Gort; M J Ecay; G Matthijs; M Ugarte; C Pérez-Cerdá
Journal:  JIMD Rep       Date:  2011-06-22

3.  Mutations in PMM2 that cause congenital disorders of glycosylation, type Ia (CDG-Ia).

Authors:  G Matthijs; E Schollen; C Bjursell; A Erlandson; H Freeze; F Imtiaz; S Kjaergaard; T Martinsson; M Schwartz; N Seta; S Vuillaumier-Barrot; V Westphal; B Winchester
Journal:  Hum Mutat       Date:  2000-11       Impact factor: 4.878

4.  Borderline mental development in a congenital disorder of glycosylation (CDG) type Ia patient with multisystemic involvement (intermediate phenotype).

Authors:  R Barone; L Sturiale; A Fiumara; G Uziel; D Garozzo; J Jaeken
Journal:  J Inherit Metab Dis       Date:  2006-12-20       Impact factor: 4.982

5.  A broad spectrum of clinical presentations in congenital disorders of glycosylation I: a series of 26 cases.

Authors:  P de Lonlay; N Seta; S Barrot; B Chabrol; V Drouin; B M Gabriel; H Journel; M Kretz; J Laurent; M Le Merrer; A Leroy; D Pedespan; P Sarda; N Villeneuve; J Schmitz; E van Schaftingen; G Matthijs; J Jaeken; C Korner; A Munnich; J M Saudubray; V Cormier-Daire
Journal:  J Med Genet       Date:  2001-01       Impact factor: 6.318

6.  Thrombotic complications in patients with PMM2-CDG.

Authors:  M Linssen; M Mohamed; R A Wevers; D J Lefeber; E Morava
Journal:  Mol Genet Metab       Date:  2013-02-16       Impact factor: 4.797

7.  Congenital disorder of glycosylation type 1a: three siblings with a mild neurological phenotype.

Authors:  D Coman; J McGill; R MacDonald; D Morris; S Klingberg; J Jaeken; D Appleton
Journal:  J Clin Neurosci       Date:  2007-04-23       Impact factor: 1.961

Review 8.  Congenital disorders of glycosylation: review of their molecular bases, clinical presentations and specific therapies.

Authors:  T Marquardt; J Denecke
Journal:  Eur J Pediatr       Date:  2003-03-15       Impact factor: 3.183

Review 9.  Congenital disorders of glycosylation with emphasis on cerebellar involvement.

Authors:  Rita Barone; Agata Fiumara; Jaak Jaeken
Journal:  Semin Neurol       Date:  2014-09-05       Impact factor: 3.420

10.  Insufficient ER-stress response causes selective mouse cerebellar granule cell degeneration resembling that seen in congenital disorders of glycosylation.

Authors:  Liangwu Sun; Yingjun Zhao; Kun Zhou; Hudson H Freeze; Yun-Wu Zhang; Huaxi Xu
Journal:  Mol Brain       Date:  2013-12-04       Impact factor: 4.041

View more
  14 in total

Review 1.  Recognizable phenotypes in CDG.

Authors:  Carlos R Ferreira; Ruqaia Altassan; Dorinda Marques-Da-Silva; Rita Francisco; Jaak Jaeken; Eva Morava
Journal:  J Inherit Metab Dis       Date:  2018-04-13       Impact factor: 4.982

Review 2.  Congenital disorders of glycosylation.

Authors:  Irene J Chang; Miao He; Christina T Lam
Journal:  Ann Transl Med       Date:  2018-12

3.  Three families with mild PMM2-CDG and normal cognitive development.

Authors:  Mari-Anne Vals; Eva Morava; Kai Teeäär; Riina Zordania; Sander Pajusalu; Dirk J Lefeber; Katrin Õunap
Journal:  Am J Med Genet A       Date:  2017-04-19       Impact factor: 2.802

4.  Longitudinal volumetric and 2D assessment of cerebellar atrophy in a large cohort of children with phosphomannomutase deficiency (PMM2-CDG).

Authors:  Víctor de Diego; Antonio F Martínez-Monseny; Jordi Muchart; Daniel Cuadras; Raquel Montero; Rafael Artuch; Celia Pérez-Cerdá; Belén Pérez; Belén Pérez-Dueñas; Andrea Poretti; Mercedes Serrano
Journal:  J Inherit Metab Dis       Date:  2017-03-24       Impact factor: 4.982

5.  PMM2-CDG and sensorineural hearing loss.

Authors:  Çiğdem Seher Kasapkara; Zeren Barış; Mustafa Kılıç; Deniz Yüksel; Lies Keldermans; Gert Matthijs; Jaak Jaeken
Journal:  J Inherit Metab Dis       Date:  2017-07-31       Impact factor: 4.982

6.  Serum transferrin carrying the xeno-tetrasaccharide NeuAc-Gal-GlcNAc2 is a biomarker of ALG1-CDG.

Authors:  Per Bengtson; Bobby G Ng; Jaak Jaeken; Gert Matthijs; Hudson H Freeze; Erik A Eklund
Journal:  J Inherit Metab Dis       Date:  2015-09-03       Impact factor: 4.982

7.  A quantitative assessment of the evolution of cerebellar syndrome in children with phosphomannomutase-deficiency (PMM2-CDG).

Authors:  Natalia Lourdes Serrano; Victor De Diego; Daniel Cuadras; Antonio F Martinez Monseny; Ramón Velázquez-Fragua; Laura López; Ana Felipe; Luis G Gutiérrez-Solana; Alfons Macaya; Belén Pérez-Dueñas; Mercedes Serrano
Journal:  Orphanet J Rare Dis       Date:  2017-09-15       Impact factor: 4.123

8.  The Analysis of Variants in the General Population Reveals That PMM2 Is Extremely Tolerant to Missense Mutations and That Diagnosis of PMM2-CDG Can Benefit from the Identification of Modifiers.

Authors:  Valentina Citro; Chiara Cimmaruta; Maria Monticelli; Guglielmo Riccio; Bruno Hay Mele; Maria Vittoria Cubellis; Giuseppina Andreotti
Journal:  Int J Mol Sci       Date:  2018-07-30       Impact factor: 5.923

9.  Synaptic roles for phosphomannomutase type 2 in a new Drosophila congenital disorder of glycosylation disease model.

Authors:  William M Parkinson; Michelle Dookwah; Mary Lynn Dear; Cheryl L Gatto; Kazuhiro Aoki; Michael Tiemeyer; Kendal Broadie
Journal:  Dis Model Mech       Date:  2016-03-03       Impact factor: 5.758

10.  Stroke-Like Episodes and Cerebellar Syndrome in Phosphomannomutase Deficiency (PMM2-CDG): Evidence for Hypoglycosylation-Driven Channelopathy.

Authors:  Mercè Izquierdo-Serra; Antonio F Martínez-Monseny; Laura López; Julia Carrillo-García; Albert Edo; Juan Darío Ortigoza-Escobar; Óscar García; Ramón Cancho-Candela; M Llanos Carrasco-Marina; Luis G Gutiérrez-Solana; Daniel Cuadras; Jordi Muchart; Raquel Montero; Rafael Artuch; Celia Pérez-Cerdá; Belén Pérez; Belén Pérez-Dueñas; Alfons Macaya; José M Fernández-Fernández; Mercedes Serrano
Journal:  Int J Mol Sci       Date:  2018-02-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.